Bio-Rad Laboratories Inc (NYSE:BIO) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $615.11 million, and the earnings are expected to come in ...
Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.
Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.
Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the letter can be downloaded here.
Bio-Rad Laboratories, Inc. (NYSE: BIO) was in 44 hedge funds’ portfolios at the end of the first quarter of 2021. The all time high for this statistic is 54.
Bio-Rad Laboratories Inc., a life science research and clinical diagnostics products company, is paying $162 million in cash to acquire venture-backed biotech company QuantaLife. The sale also ...
Bio-Rad Laboratories, Inc. (BIO) Appoints John Goetz As Chief Operating Officer And Announces Other Executive Appointments HERCULES, CA-- (Marketwired - October 01, 2014) - Bio-Rad Laboratories ...
Our AI model demonstrates 64% historical accuracy for BIO predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
VAR_0__株価予測に影響を与える要因は何か?
当社の分析では、BIO-RAD LABORATORIES, INC.の財務指標、Industrial Applications and Servicesセクターの動向、市場センチメント、テクニカル指標、業績データ、株価に影響を与えるマクロ経済要因を考慮しています。